Now available at Greater Miami Skin and Laser Center:
Introducing LATISSE™
We’re pleased to introduceLATISSE™ (bimatoprost ophthalmicsolution) 0.03%—the first and onlyFDA-approved prescriptiontreatment forhypotrichosisusedto grow eyelashes, making themlonger, thicker, and darker.
Eyelash hypotrichosis is another name for havinginadequate or not enough eyelashes.BeforeBeforeAfterAfterAVAILABLETODAY!
LATISSE™ has been studied in clinical trials to demonstrate itssafety and effectiveness. To see more results or learn more, visit
www.latisse.com and www.miamiskinandlaser.com.
Important Safety Information
Do not use LATISSE™solutionifyouareallergictooneofitsingredients.
LATISSE™solution is intended for use on the skin of the upper eyelid margins atthebaseoftheeyelashes.DONOTAPPLYtothelowereyelid.Ifyouhaveahistory of abnormal intraocular pressure (IOP), you should only use LATISSE™under theclosesupervisionofyourphysician.
LATISSE™usemaycausedarkeningoftheeyelidskinwhichmaybereversible. Although not reported in clinical studies, LATISSE™use may also cause increasedbrown pigmentation of the colored part of the eye which is likely to be permanent.
You should tell your physician you are using LATISSE™especiallyifyouhaveahistory of eye pressure problems. You should also tell anyone conducting an eye pressurescreening that you are using LATISSE™.
The most common side effects after using LATISSE™solutionareanitchingsensation intheeyesand/oreyeredness.Thiswasreportedinapproximately4%ofpatients. LATISSE™solutionmaycauseotherlesscommonsideeffectswhichtypicallyoccur on the skin close to where LATISSE™isapplied,orintheeyes.Theseincludeskin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.
Click here for full prescribing information.
Come in today for the newest innovation in lashes.
Ask if LATISSE™ is right for you.
1.LATISSE™ Prescribing Information.
©2009 Allergan, Inc., Irvine, CA 92612 ™marks owned by Allergan, Inc.www.latisse.comAPC23YA09 900504
